These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21464059)

  • 1. Dabigatran etexilate: a new oral thrombin inhibitor.
    Hankey GJ; Eikelboom JW
    Circulation; 2011 Apr; 123(13):1436-50. PubMed ID: 21464059
    [No Abstract]   [Full Text] [Related]  

  • 2. Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.
    Med Lett Drugs Ther; 2010 Nov; 52(1351):89-90. PubMed ID: 21068702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
    Eisert WG; Hauel N; Stangier J; Wienen W; Clemens A; van Ryn J
    Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):1885-9. PubMed ID: 20671233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
    Stangier J; Clemens A
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?].
    Gassanov N; Caglayan E; Erdmann E; Er F
    Dtsch Med Wochenschr; 2010 Feb; 135(6):256-9. PubMed ID: 20104442
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).
    Van de Werf F; Brueckmann M; Connolly SJ; Friedman J; Granger CB; Härtter S; Harper R; Kappetein AP; Lehr T; Mack MJ; Noack H; Eikelboom JW
    Am Heart J; 2012 Jun; 163(6):931-937.e1. PubMed ID: 22709744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.
    Eriksson BI; Friedman RJ
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():25S-31S. PubMed ID: 19648146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.
    Dahl OE
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():17S-24S. PubMed ID: 19696041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.
    Stangier J; Stähle H; Rathgen K; Roth W; Shakeri-Nejad K
    J Clin Pharmacol; 2008 Dec; 48(12):1411-9. PubMed ID: 18827075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran etexilate: future directions in anticoagulant treatment.
    Schulman S; Reilly PA
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():32S-41S. PubMed ID: 19679590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Patient's Guide to Taking Dabigatran Etexilate.
    Spinler SA; Willey VJ
    Circulation; 2011 Aug; 124(8):e209-11. PubMed ID: 21859976
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral antithrombotic inhibitors: dabigatran etexilate, meeting an unmet need?
    Hull R
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():5S-8S. PubMed ID: 19706619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thrombin inhibitor shows stable safety profile in the practice].
    MMW Fortschr Med; 2008 Dec; 150(51-52):38-9. PubMed ID: 19149309
    [No Abstract]   [Full Text] [Related]  

  • 14. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
    van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
    Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.
    Avecilla ST; Ferrell C; Chandler WL; Reyes M
    Am J Clin Pathol; 2012 Apr; 137(4):572-4. PubMed ID: 22431533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE; Spinler SA
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
    Eriksson BI; Dahl OE; Ahnfelt L; Kälebo P; Stangier J; Nehmiz G; Hermansson K; Kohlbrenner V
    J Thromb Haemost; 2004 Sep; 2(9):1573-80. PubMed ID: 15333033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
    Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
    Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
    Ma TK; Yan BP; Lam YY
    Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.
    Ieko M
    Curr Opin Investig Drugs; 2007 Sep; 8(9):758-68. PubMed ID: 17729188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.